21.79
4.93%
-1.13
Dopo l'orario di chiusura:
21.13
-0.66
-3.03%
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownHere's Why - MarketBeat
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Occidental Petroleum Corp (OXY-N) QuotePress Release - The Globe and Mail
Nurix Therapeutics Presents Preclinical Data from Two - GlobeNewswire
Nurix Reports Strong Preclinical Data for Two Novel Autoimmune Disease Treatments | NRIX Stock News - StockTitan
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.7%Should You Sell? - MarketBeat
Redmile Group, LLC Expands Stake in Nurix Therapeutics Inc - GuruFocus.com
Significant Stake Increase by Baker Bros. Advisors in Nurix Ther - GuruFocus.com
WASATCH ADVISORS LP Adjusts Stake in Nurix Therapeutics Inc - GuruFocus.com
When the Price of (NRIX) Talks, People Listen - Stock Traders Daily
Conocophillips (COP-N) QuotePress Release - The Globe and Mail
Wellington Management Group LLP Increases Stake in Nurix Therape - GuruFocus.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by International Assets Investment Management LLC - Defense World
ARK Investment Management LLC Has $49.80 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $27.61 By Investing.com - Investing.com Canada
Morgan Stanley's Strategic Reduction in Nurix Therapeutics Holdi - GuruFocus.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighHere's Why - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $27.61 - Investing.com India
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25% - Simply Wall St
Cisco Systems Inc (CSCO-Q) QuotePress Release - The Globe and Mail
The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts - Benzinga
Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com India
SEC Form 424B5 filed by Nurix Therapeutics Inc. - Quantisnow
Nurix therapeutics' chief legal officer sells $82,250 in stock By Investing.com - Investing.com UK
(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India
Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St
Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com Australia
Nurix therapeutics chief legal officer sells shares worth over $101k By Investing.com - Investing.com South Africa
Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia
Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Magna International Inc (MG-T) QuotePress Release - The Globe and Mail
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 - Investing.com India
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):